Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | CASP9 | P55211 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921663 | 0.83 | TSHR (0.57) | TSHRCA12CA9PARP1PDPK1 | |
| SCHEMBL3921668 | 0.83 | TSHR (0.57) | TSHRCA12CA9PARP1PDPK1 | |
| SCHEMBL3926780 | 0.83 | TSHR (0.57) | TSHRCA12CA9PARP1PDPK1 | |
| SCHEMBL8966129 | 0.83 | TSHR (0.62) | TSHRHTR2ACA12CA9PARP1 | |
| SCHEMBL3926777 | 0.83 | TSHR (0.57) | TSHRCA12CA9PARP1PDPK1 | |
| SCHEMBL7099999 | 0.83 | TSHR (0.57) | TSHRCA12CA9PARP1PDPK1 | |
| SCHEMBL15184731 | 0.79 | TSHR (0.53) | TSHRCA12CA9PARP1PDPK1 | |
| SCHEMBL21591323 | 0.79 | TSHR (0.53) | TSHRCA12CA9PARP1PDPK1 | |
| SCHEMBL10050308 | 0.78 | TSHR (0.55) | TSHRCA12CA9PARP1ACHE | |
| SCHEMBL30193337 | 0.77 | TSHR (0.62) | TSHRHTR2ACA12CA9PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917194-B1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2917194-B1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | LILLY CO ELI (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9416138-B2 | Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416138-B2 | Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416138-B2 | Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors | ELI LILLY AND COMPANY (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY | 2015-10-08 | — | — | US | disclosed |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY | 2015-10-08 | — | — | US | disclosed |
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY | 2015-10-08 | — | — | US | disclosed |
| EP-2917194-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | Eli Lilly and Company (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014074365-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014074365-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2014-05-15 | — | — | WO | disclosed |
| EP-1450796-B1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| US-6596718-B1 | A compound of formula I has a good affinity to the A2A receptor and is useful for the treatment of diseases mediated by this receptor. | HOFFMANN-LA ROCHE INC. | 2003-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284404-A1 | NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS | MOGAT2, SOAT1, SOAT2 | TSHR 2001/4885HTR2A 2783/4885CA12 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.